NASDAQ
Biodesix, Inc. (BDSX)
♥ 417 Thanks from members
Biodesix, Inc. (BDSX) garners a 'Strong Buy' consensus from Wall Street analysts with a raised FY2026 revenue guidance of $108M–$114M. However, despite strong diagnostic adoption and clinical data, analysts note high cash burn and historical balance sheet vulnerabilities.